{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-040051","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-06-03T13:02:51+00:00","discovered_at":"2026-06-03T13:04:06.848663+00:00","generated_at":"2026-06-03T13:04:16.040653+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Crescent Biopharma shareholders re-elect directors, ratify auditor, approve say-on-pay","bullets":["Jonathan Violin, Ph.D. elected Class II director with 2,890,000 votes (all from preferred shares).","Susan Moran, M.D., MSCE elected Class II director with 21,401,136 votes FOR; 136,056 WITHHELD.","Ratification of PricewaterhouseCoopers as auditor approved with 21,049,101 FOR (1,452 against).","Non-binding say-on-pay approved: 18,346,099 FOR; 300,217 AGAINST. Board set future vote every 1 year."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-040051","json":"https://secwatch.observer/filing/0001628280-26-040051.json","markdown":"https://secwatch.observer/filing/0001628280-26-040051.md","text":"https://secwatch.observer/filing/0001628280-26-040051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/cbio-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:04:16.040653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f6fae34dc17a8f83e2932703079774577fba621","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,049,101 1,452 154 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"515c71f7e4bedffc5e90540f5eb0657d23eb0311","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. 1 YEAR 2 YEARS 3 YEARS Votes ABSTAINED Broker Non-Votes 18,644,881 903 887 521 2,403,515","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"8749948e009eabb79d53397d0a0648a15955dde3","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 18,346,099 300,217 876 2,403,515","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"9b7e850d3c34bc9636d45a9d51b77e475410c174","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Election of two Class II directors to serve until the Company's 2029 Annual General Meeting of Shareholders at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 1A and Proposal No. 1B - Election of two Class II directors to serve until the Company’s 2029 Annual General Meeting of Shareholders and until their respective successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. Votes FOR Votes WITHHELD Broker Non-Votes Jonathan Violin, Ph.D. (Proposal No. 1A) 2,890,000 0 0 Susan Moran, M.D., MSCE (Proposal No. 1B) 21,401,136 136,056 2,403,515","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}